African-Americans with hepatitis C virus (HCV) genotype 1 infections have lower ribavirin plasma exposures than Caucasian Americans when treated with weight-based ribavirin plus peginterferon.
when they reach plasma exposure thresholds, African-American patients
are just as likely to achieve viral responses as Caucasians.
results provide important new insights into the basis for the racial
disparity in the treatment responses to peginterferon and ribavirin
treatment for HCV genotype 1,” say Charles Horwell (University of
Maryland, Baltimore, USA) and colleagues.